Penumbra, Inc. $PEN Shares Sold by Sei Investments Co.

Sei Investments Co. lessened its holdings in Penumbra, Inc. (NYSE:PEN) by 67.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,744 shares of the company’s stock after selling 59,671 shares during the quarter. Sei Investments Co.’s holdings in Penumbra were worth $9,439,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Geode Capital Management LLC increased its holdings in shares of Penumbra by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 766,510 shares of the company’s stock valued at $238,365,000 after acquiring an additional 18,738 shares during the last quarter. Invesco Ltd. raised its position in shares of Penumbra by 1.1% during the 4th quarter. Invesco Ltd. now owns 638,305 shares of the company’s stock worth $198,455,000 after acquiring an additional 7,211 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in Penumbra by 165.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 594,112 shares of the company’s stock worth $184,715,000 after purchasing an additional 370,636 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Penumbra by 1.5% in the fourth quarter. Janus Henderson Group PLC now owns 475,898 shares of the company’s stock valued at $147,962,000 after purchasing an additional 7,050 shares in the last quarter. Finally, Capital World Investors boosted its holdings in Penumbra by 2.6% in the fourth quarter. Capital World Investors now owns 426,456 shares of the company’s stock valued at $132,589,000 after purchasing an additional 10,724 shares in the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Penumbra to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada restated a “sector perform” rating and issued a $374.00 target price on shares of Penumbra in a report on Thursday, June 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research report on Friday, July 17th. Zacks Research lowered shares of Penumbra from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, Citigroup reduced their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Penumbra presently has a consensus rating of “Hold” and a consensus price target of $367.07.

Penumbra Trading Up 0.5%

NYSE:PEN opened at $321.40 on Friday. The company has a market capitalization of $12.64 billion, a PE ratio of 78.97, a P/E/G ratio of 1.99 and a beta of 0.70. Penumbra, Inc. has a 52-week low of $221.26 and a 52-week high of $362.41. The stock’s 50 day moving average price is $318.75 and its 200 day moving average price is $330.03. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). The firm had revenue of $390.05 million during the quarter, compared to analysts’ expectations of $389.64 million. Penumbra had a net margin of 10.67% and a return on equity of 10.70%. Penumbra’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.86 EPS. On average, research analysts anticipate that Penumbra, Inc. will post 5.02 EPS for the current year.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.